Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical.
DA
Draper Associates
Activity from announced rounds
Activity in this selectionUnited States · Oct 4, 2026 · Jul 7, 2026
- Rounds participated in
- 4
- Confirmed lead rounds
- 0 2 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $175M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionCloverleaf Bio
$33MSeed
ParticipantPoseidon Aerospace
Poseidon Aerospace is developing unmanned cargo aircraft for commercial freight and defense logistics. Its Egret short-takeoff-and-landing freighter and Heron seaplane are designed to move heavy loads between small, remote or water-based operating sites without an onboard pilot.
$11MSeed
ParticipantAurelius Systems
Develops AI-powered autonomous directed-energy systems to detect and neutralize drone threats
$40MSeries A
Role not disclosedVenus Aerospace
Building next-generation propulsion systems for defense, space, and future high-speed flight
$91MSeries B
Role not disclosed